Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy ... cells from a patient, editing them to produce blood cells that do not form the ...

Vertex has entered a reimbursement agreement with NHS England enabling eligible SCD patients to access Casgevy in the public health system.

In clinical trials, all patients who received the therapy avoided a hospitalisation for a year following treatment, and almost 98% had still avoided hospitalisation around 3.5 years later. The list ...

The CRISPR-based gene therapy Casgevy ... currently available – Casgevy does not carry the same risk of rejection. However, it is only recommended for patients who are eligible for a transplant ...

patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). The reimbursement agreement comes as the National Institute for Health and Care Excellence (NICE ...

CASGEVY, a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy, is approved for eligible SCD and TDT patients 12 years and older by multiple regulatory bodies around the world. The Conditional ...

Separately, Vertex also announced a reimbursement agreement with NHS England for CASGEVY, its CRISPR/Cas9 gene-edited therapy for sickle cell disease. The deal ensures that eligible patients in ...

Vertex Pharmaceuticals (VRTX) announced a reimbursement agreement with NHS England for eligible sickle cell disease patients to access the CRISPR/Cas9 gene-edited therapy, Casgevy. The ...

Campaigners reacted with joy as health officials approved a gene-editing therapy for certain ... and Care Excellence (Nice) approved Casgevy for certain patients with the genetic condition.